Quantcast
Home > Quotes > VNDA
VNDA

Vanda Pharmaceuticals Inc. Common Stock (VNDA) Quote & Summary Data

$22.45
*  
0.12
0.53%
Get VNDA Alerts
*Delayed - data as of Nov. 14, 2018 14:38 ET  -  Find a broker to begin trading VNDA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    VNDA Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 22.44 / $ 22.47
Today's High / Low
$ 23.05 / $ 22.0444
Share Volume
269,990
50 Day Avg. Daily Volume
1,076,598
Previous Close
$ 22.57
52 Week High / Low
$ 25.07 / $ 12.70
Market Cap
1,177,499,806
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
269,990
50 Day Avg. Daily Volume:
1,076,598

P/E Ratio

P/E Ratio:
93.54
Forward P/E (1y):
565.50
Earnings Per Share (EPS):
$ 0.24

Trading Range

The current last sale of $22.45 is 76.77% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 23.05 $ 25.07
 Low: $ 22.0444 $ 12.70

Company Description (as filed with the SEC)

Vanda Pharmaceuticals Inc. (we, our, the Company or Vanda) is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. Vanda commenced its operations in 2003 and our product portfolio includes: * HETLIOZ® (tasimelteon), a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24), was approved by the U.S. Food and Drug Administration (FDA) in January 2014 and launched commercially in the U.S. in April 2014. In July 2015, the European Commission (EC) granted centralized marketing authorization with unified labeling for HETLIOZ® for the treatment of Non-24 in totally blind adults. HETLIOZ® was commercially launched in Germany in August 2016.  ... More ...  


Risk Grade

Where does VNDA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 22.75
Open Date:
Nov. 14, 2018
Close Price:
$ 22.57
Close Date:
Nov. 13, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x